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Abstract  
Background: Breast cancer (BC) is a heterogeneous disease characterised by variant biology 
and patient outcome. The amino acid transporter, SLC7A5, plays a role in BC although its 
impact on patient outcome in different BC subtypes remains to be validated. This study aimed 
to determine whether the clinicopathological and prognostic value of SLC7A5 is different 
within the molecular classes of BC. 
Methods: SLC7A5 was assessed at the genomic, using METABRIC data (n=1,980), and 
proteomic, using immunohistochemistry and TMA (n= 2664; 1,110 training and 1,554 
validation sets), levels in well-characterised primary BC cohorts. SLC7A5 expression was 
correlated with clinicopathological and biological parameters, molecular subtypes, and patient 
outcome. 
Results: SLC7A5 mRNA and protein expression were strongly correlated with larger tumour 
size, and higher grade. High expression was observed in triple negative (TN), HER2+, and 
luminal B subtypes. SLC7A5 mRNA and protein expression was significantly associated with 
the expression of the key regulator of tumour cell metabolism c-MYC, specifically in Luminal 
B tumours only (p=0.001). High expression of SLC7A5 mRNA and protein was associated 
with poor patient outcome (p <0.001) but only in the highly proliferative ER+/ luminal B 
(p=0.007) and HER2+ classes of BC (p=0.03). In multivariate analysis, SLC7A5 protein was 
independent risk factor for shorter Breast Cancer Specific Survival only in ER+ high 
proliferation tumours (p=0.02). 
Conclusions: SLC7A5 appears to play a role in the aggressive highly proliferative ER+ 
subtype driven by MYC and could act as a potential therapeutic target. Functional assessment 
is necessary to reveal the specific role played by this transporter in the ER+highly proliferative 
subclass and HER2+ subclass of BC. 
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Introduction 
Altered metabolic pathways have been readily accepted as part of the revised hallmarks of 
cancer where cancer cells are able to regulate their metabolism to provide energy and cellular 
building blocks required for their unremitting proliferation [1]. Many cancer cells are highly 
reliant on amino acids for their growth, not only because they are a nitrogen donor for the 
synthesis of nucleotides and other amino acids, but also because they activate mammalian 
target of rapamycin complex1 (mTORC1) through nutrient signalling pathways which in turn 
regulates protein translation and cell growth [2, 3]. There is also increasing evidence that 
oncogenes and/or tumour-suppressor genes can reprogram tumour cell metabolism including 
the direct regulation of the amino acid transporter, solute carrier family 7 member 5 (SLC7A5), 
by the oncogene MYC [4, 5] and the regulation of the glutamine transporter, SLC1A5, 
expression by the tumour suppressor Retinoblastoma (Rb) [6]. 
 SLC7A5 is a sodium-independent transporter and acts as an amino acid exchanger by 
transporting large neutral amino acids such as leucine, phenylalanine and tryptophan by 
exchange with intracellular glutamine [7]. It therefore functions in supplying amino acids to 
cancer cells as well as maintaining intra-cellular leucine which is considered a master regulator 
of the mTORC1 signalling pathway [8-10]. For functional expression on the plasma membrane, 
SLC7A5 must heterodimerise with the heavy chain of SLC3A2 [7, 11]. 
It has been reported that SLC7A5 is highly expressed in a variety of cancers including 
oesophageal carcinoma [12], oral cancer [13] and lung adenocarcinoma [14]. SLC7A5 is co-
expressed with the glutamine transporter, SLC1A5, in many cancers suggesting a functional 
coupling of these transporters in supporting tumour progression [15]. In this study, we aimed 
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to assess SLC7A5 gene copy number and mRNA expression, alongside protein expression in 
large and well-characterised annotated cohorts of BC to determine its biological, 
clinicopathological and prognostic value in the different BC molecular classes with particular 
interest in the highly proliferative aggressive subgroups.   
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Material and methods 
SLC7A5 copy number and gene expression 
A cohort of 1,980 BC tumours in the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) [16] was used to evaluate SLC7A5 gene copy number aberrations 
(CNA) and gene expression. DNA/RNA was isolated from fresh frozen samples and genomic 
and transcriptional profiling were obtained using the Affymetrix SNP 6.0 and Illumina HT-
12v3 platforms respectively. CNA were considered at the gene level by segments and Šidák 
correction [17] was applied for multiple testing. Gene expression data was pre-processed and 
normalised as described previously [16]. In this cohort, patients included were ER+ and /or 
Lymph Node negative (LN-) did not receive adjuvant chemotherapy, whereas ER- and LN+ 
patients received adjuvant treatment. X-tile (version 3.6.1, Yale University, USA) was applied 
to dichotomise SLC7A5 mRNA expression, based on prediction of Breast Cancer Specific 
Survival (BCSS). The association between the SLC7A5 mRNA expression and 
clinicopathological parameters, molecular subtypes, and patient outcome was investigated. 
 
The online dataset, Breast Cancer Gene Expression Miner v4.0 
(http://bcgenex.centregauducheau.fr) and the breast cancer TCGA data [18] were used for 
external validation of SLC7A5 copy number/ or mRNA expression. 
 
Patients and tumours 
This study evaluated well-characterised cohorts of early stage primary operable invasive BC 
patients, who presented aged ≤ 70 years. Patients in the discovery set (n=1110) presented at 
Nottingham City Hospital between 1989 and 1998, while the validation set (n=1554) includes 
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patients who were presented between 1998 and 2006. Patient management was uniform and 
based on tumour characteristics by Nottingham Prognostic Index (NPI) and hormone receptor 
status. Patients within the NPI excellent prognostic group (score ≤3.4) received no adjuvant 
therapy, but those patients with NPI > 3.4 received tamoxifen if ER-positive [± Goserelin 
(Zoladex) in case the patients were premenopausal]. Conversely, classical cyclophosphamide, 
methotrexate and 5-flurouracil (CMF) were used if the patients were ER negative and fit 
enough to receive chemotherapy. None of the patients in this study received neoadjuvant 
therapy.  Clinical history, tumour characteristics, information on therapy and outcomes are 
prospectively maintained. Outcome data included development and time to distant metastasis 
(DM) and Breast Cancer Specific Survival (BCSS).  
There was no difference in the distribution of clinicopathological parameters between the 
discovery and validation cohorts or the METABRIC series of patients (all correlation 
coefficient ≥0.91, all p<0.0001) (Supplementary Table 1). 
Western Blotting 
The antibody specificity of anti-SLC7A5 (EPR17573, Abcam, UK) was validated using 
Western blotting in human embryonic Kidney (HEK) 293T over expression lysate (Origene 
Technologies, Rockville, MD, USA) and MDA-MB-175 (Luminal B-like), T47D and MCF7 
(Luminal A) [19] breast cancer lysate (American Type Culture Collection; Rockville, MD, 
USA). A dilution of 1:200 of the primary antibody and 1:1000 HRP conjugated (Dako) 
secondary antibodies were applied.  5% milk /PBS-Tween (0.1%) (Marvel Original Dried 
Skimmed Milk, Premier Food Groups Ltd., UK) was used for blocking. Mouse monoclonal 
anti-β-actin primary antibody was used as a marker of endogenously expressed control. 
SLC7A5 bands were visualised using Enhance Chemiluminescence (ECL) showing a single 
specific band at the correct predicted size (40 KDa) for the SLC7A5 protein. 
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Tissue arrays and Immunohistochemistry 
The discovery set (n=1,110) were arrayed as previously described using a single 0.6mm core 
sampled from the periphery of each invasive tumour [20]. The validation set (n=1,554) were 
similarly arrayed using a TMA GrandMaster (3D Histech). Immunohistochemical staining was 
performed on 4 μm TMA sections using Novolink polymer detection system (Leica 
Biosystems, RE7150-K). Briefly, tissue slides were deparaffinised with xylene and rehydrated 
through 3 changes of alcohol. Heat-induced antigen epitope retrieval was performed in citrate 
buffer (pH 6.0) for 20 minutes using a microwave oven (Whirpool JT359 Jet Chef 1000W). 
Endogenous peroxidase activity was blocked by Peroxidase Block for 5 minutes. Slides were 
washed with Tris-Buffered Saline (TBS, pH 7.6), followed by application of Protein Block for 
5 minutes. Following another TBS wash, sections were incubated with the primary SLC7A5 
antibody diluted at 1:50 in Leica antibody diluent (RE AR9352, Lieca, Biosysytems, UK) 
overnight at 4°C. Slides were washed with TBS followed by incubation with Post Primary 
Block for 30 minutes followed by a TBS wash. Novolink polymer was applied for 30 minutes. 
3,3'-diaminobenzidine (DAB) chromogen was applied for 5 minutes. Slides were counterstained 
with Novolink haematoxylin for 6 minutes, dehydrated and coverslipped.  
Stained TMA sections were scored using high resolution digital images (NanoZoomer; 
Hamamatsu Photonics, Welwyn Garden City, UK), at x20 magnification. Evaluation of 
staining for SLC7A5 was based on a semi-quantitative assessment of cores’ digital images 
using a modified histochemical score (H-score) which includes an assessment of both the 
intensity and the percentage of stained cells [21]. Staining intensity was assessed as follows 0, 
negative; 1, weak; 2, medium; 3, strong and the percentage of the positively stained tumour 
cells was estimated subjectively. The final H-score was calculated multiplying the percentage 
of positive cells (0-100) by the intensity (0-3), producing a total range of 0-300. 
8 
 
Dichotomisation of protein expression was determined using x-tile software in predicting 
BCSS.   
 
Immunhistochemical staining and dichotomisation of the other biomarkers included in this 
study were as per previous publications [20, 22-30]. ER and PgR positivity was defined as ≥1% 
staining. Immunoreactivity of HER2 in TMA cores was scored using standard HercepTest 
guidelines (Dako). Chromogenic in situ Hybridisation (CISH) was used to quantify HER2 gene 
amplification in borderline cases using the HER2 FISH pharmDx™ plus HER2 CISH 
pharmDx™ kit (Dako) and was assessed according to the American Society of Clinical 
Oncology guidelines. BC molecular subtypes were defined, based on  tumour IHC profile and 
the Elston-Ellis [31] mitotic score as: ER+/HER2- Low Proliferation (mitotic score 1), 
ER+/HER2- High Proliferation (mitotic score 2 and 3), HER2-positive class: HER2+ 
regardless of ER status, Triple Negative: ER-, PgR- and HER2- [32]. Basal-like phenotype was 
defined as those tumours expressing cytokeratin (Ck) 5/6, and/or Ck14 and/or Ck17.  
 
Statistical analysis 
Statistical analysis was performed using SPSS 22.0 statistical software (SPSS Inc., Chicago, 
IL, USA). Spearman’s correlation coefficient was carried out to examine the association 
between continuous variables. The chi-square test was performed for inter-relationships 
between categorical variables. For the continuous variables, differences between 3 or more 
groups were assessed using one way analysis of variance (ANOVA) with post-hoc Tukey 
multiple comparison test (for normalised data) or Kruskal-Wallis test (for non-normal 
distribution). Differences between two groups were assessed using t-test (normalised data) or 
Mann-Whitney test (non-normal distribution). Survival curves were analysed by Kaplan-Meier 
with Log Rank test. Cox’s proportional hazard method was performed for multivariate analysis 
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to identify the independent prognostic/predictive factors. P-values were adjusted using 
Bonferroni correction for multiple testing. A p-value ˂0.05 was considered significant. The 
study endpoints were 10-year BCSS or Distant Metastasis Free Survival (DMFS). 
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Results 
SLC7A5 genomic profiling  
SLC7A5 was amplified in 0.3% and 0.6% of BC cases in the METABRIC and TCGA datasets, 
respectively, while deletion (deep and shallow) was detected in 56% and 68% of cases in the 
same cohorts respectively. Point mutations in SLC7A5 were extremely rare, where TCGA data 
reported just one case with a missense mutation (Supplementary figure 4A) [33, 34]. SLC7A5 
is situated on chromosome 16 (16q24.2), all the annotated genes, which located on 16q [35] 
were selected to determine their CNV in relation to SLC7A5 and assess whether these 
aberrations were locus-specific or involving large chromosomal segments. Both METABRIC 
and TCGA data showed a significant positive correlation between SLC7A5 deletion and the 
deletion of all genes (p<0.001, Supplementary table 2). However, amplification of three genes 
(FANCA, CBFA2T3 and CDT1) showed significant association with the amplified SLC7A5 
(p≤0.03, data not shown) in the above-mentioned datasets together.  
 
SLC7A5 expression in breast cancer  
SLC7A5 protein expression was observed, predominantly in the membrane of invasive breast 
cancer cells, with expression levels varying from absent to high (Figure 1B and 1C). The 
distribution of the SLC7A5 protein expression was unimodal and left-skewed. The SLC7A5 
mRNA expression had a normal distribution. Expression of SLC7A5 mRNA and protein were 
dichotomised using cut points derived from prediction of patient survival using X-tile 
(http://tissuearray.org; Yale University). Positive SLC7A5 expression (>15 H-score) was 
observed in 191/1,110 (17%) and 268/1,554 (17%) of cases in the discovery and validation sets 
respectively, while high SLC7A5 mRNA expression (log2 intensity >8) was observed in 
1,019/1,923 (53%) of the METABRIC breast cancer cases. A total of 49/1,980 (2.4%) of cases 
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showed a copy number (CN) gain of SLC7A5 and 530/1,980 (26.7%) showed a CN loss. A 
significant association was observed between SLC7A5 copy number variation (CNV) and 
SLC7A5 mRNA expression (p<0.001, Figure 2).  
 
SLC7A5 and clinicopathological parameters 
Table 1 summarises the associations between SLC7A5 protein expression including larger 
tumour size, high tumour grade, and poor NPI (all p<0.001). Regarding BC metastatic sites, 
high SLC7A5 protein levels were associated with the development of distant metastases to the 
brain (p<0.001) and lung (p=0.04), while there was no association with developing DM to the 
bone or liver.  
 
High SLC7A5 mRNA expression was significantly associated with larger tumour size (Figure 
3A, p<0.001), higher grade (Figure 3B, p<0.001), positive nodal metastasis (Figure 3C, 
p<0.001) and poor NPI (Figure 3D, p<0.001). Both SLC7A5 mRNA and SLC7A5 protein were 
associated with medullary-like tumours. Where data was available, these associations were 
confirmed using the Breast Cancer Gene-Expression Miner v4.0 (Supplementary figure 1A, 
1B) and the TCGA data (Supplementary figure 4B),.  In addition SLC7A5 copy number loss 
was significantly associated with good prognostic parameters including, lower grade and good 
NPI (Table 2, p<0.001). There was a positive association between SLC7A5 copy number gain 
and MYC gain (p<0.001, Table 2). 
 
 
SLC7A5 expression in molecular BC subtypes 
SLC7A5 protein expression was associated with negative hormone receptor status and HER2+ 
tumours (all p≤0.002, Table 3A) and it was highly expressed in Triple Negative (TN) and basal-
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like phenotype malignancies compared to non-TN and non-basal-like tumours (p<0.001, Table 
3A). Similarly, high expression of SLC7A5 mRNA was significantly associated with hormone 
receptor negative (ER- and PR-) and HER2+ tumours (all p<0.001, Table 3B). These results 
were in concordance with the findings of the Breast Cancer Gene-Expression Miner v4.0 
(Supplementary Figure 1C-F) and TCGA data analysis (Supplementary figure 4C-4E).  
 
When comparing the levels of SLC7A5 mRNA expression in the intrinsic (PAM50) subtypes 
[36], high expression was observed in Basal-like, HER2+ and Luminal B tumours (Figure 3F, 
p<0.001). Similarly, within the METABRIC Integrative Clusters, high SLC7A5 mRNA 
expression was associated with clusters 5 (ERBB2 amplified), 9 (Luminal B subgroup) and 10 
(TN/basal-like) (p<0.001, Figure 3E). In the SCMGENE subtypes there was a higher 
expression of SLC7A5 mRNA in the ER+/HER2- high proliferation class (Luminal B) 
compared with the ER+/HER2- low proliferation class (Luminal A) (p<0.001, Figure 3G). 
Association of SLC7A5 mRNA with PAM50 subtypes was confirmed using the Breast Cancer 
Gene-Expression Miner v4.0 (Supplementary Figure 1G). Expression of SLC7A5 protein in 
the defined molecular subtypes showed a lower expression in the low proliferation tumours 
compared with the other subtypes (p<0.001, Table 1). 
 
At the gene level, Basal-like showed a greater copy number gain of SLC7A5 (p<0.001, Table 
2), while SCL7A5 copy number loss was mainly observed in the Luminal A subtype (p<0.001, 
Table 2).  
 
SLC7A5 expression and other associated markers 
The correlation of SLC7A5 mRNA with associated genes, using the METABRIC dataset, was 
investigated (Table 4). The genes were selected based on previous publications, being either a 
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regulatory genes or others that share or support the SLC7A5 biological function which focused 
mainly in glutamine transport and glutamine metabolism [2, 5, 15, 37-41]. There was a positive 
correlation between SLC7A5 mRNA expression and the expression of regulatory genes, 
several amino acid transporters and genes involved in the glutamine-proline regulatory axis. 
There was a positive relationship between SLC7A5 and MYC, mTOR and ATF4 (p<0.001) 
and the positive relationship between MYC, HIF2A and SLC7A5 was only observed in 
Luminal B tumours (p=0.01 and p <0.001 respectively).  
High SLC7A5 mRNA expression was specifically associated with the enzymes involved with 
conversion of Glutamine (Gln) to proline, where PYCR1 and ALDH18A1 showed a positive 
relationship with SLC7A5 in almost all subtypes (p<0.02). 
The majority of glutamine transporters were significantly associated with SLC7A5 expression 
primarily in triple negative tumours and to a lesser extent Luminal and HER2+ subtypes. 
SLC7A5 was significantly correlated with SLC1A5 in all subtypes (p<0.02). 
TP53 mutations were also highly prevalent in breast tumours where there was high SLC7A5 
mRNA expression (p<0.001, Table 3). Moreover, high SLC7A5 protein was positively 
associated with high p53 protein (p<0.001).  
SLC7A5 protein expression was significantly expressed in breast tumours with high Ki67, and 
the upstream effector MYC (p<0.001, Table 5). The other investigated markers include the 
glutamine transporter SLC1A5 and other proteins involved in the glutamine metabolic 
pathways, as well as downstream signaling mTORC1. SLC1A5, GLS, PYCR1 and PIK3CA 
were significantly expressed in breast tumours with high expression of SLC7A5 (p<0.001), 
while the low expression was associated with high levels of p-mTORC1 (p<0.001) (Table 5).  
SLC7A5 expression and patient outcome 
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Both high SLC7A5 mRNA (p<0.001) (Figure 4A) and protein (p<0.001) expression, in the 
discovery and validation sets, were associated with poor BCSS (Figure 5A, 5B). This 
association is anticipated as the cutoff was based on the prediction of BCSS. 
While SLC7A5 mRNA expression was not predictive for BCSS in any specific molecular class 
(Figure 4B-4E), high expression of SLC7A5 protein was only predictive of shorter BCSS in 
ER+ high proliferation (p=0.007, Figure 5D) and HER2+ tumours (p=0.03, Figure 5F). There 
was no association between SLC7A5 protein and outcome in ER+ low proliferation (Figure 
5C) or in TNBC (Figure 5E). In multivariate Cox regression analysis, SLC7A5 mRNA was a 
predictor of shorter BCSS independent of tumour size, grade, and lymph node stage (p=0.006, 
Supplementary table 3) but not in any specific subtype. However, SLC7A5 protein showed a 
significant result only in the ER+ high proliferation tumours (p=0.02, Table 6) and not with 
any other subtypes (data not shown).  
 
 
Likewise, high SLC7A5 protein expression was associated with shorter distant metastases-free 
survival (DMFS) (p<0.001; Supplementary Figure 2A, 2B) within the ER+ high proliferation-
class (p=0.03, Supplementary Figure 2D) but not with other subtypes (Supplementary Figure 
2C, 2E, 2F). This association was found in the discovery set and validated in the validation set. 
The relationship between high SLC7A5 mRNA expression and poor patient outcome in ER+ 
disease, but not ER- disease, was confirmed using Breast Cancer Gene-Expression Miner 
(Supplementary figure 3A, 3B, 3C).  
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Discussion  
Breast cancer is a heterogeneous disease with various subtypes [42] differing in terms of 
morphology, molecular and biological profiles, response to therapy and clinical behaviour. In 
addition, different subtypes exhibit disparity in their metabolic pathways and their nutritional 
needs. The most common form of BC (~55-80%) is ER+/luminal tumours [43, 44], and those 
that belong to this class are also variable in terms of recurrence, mortality rates and disease 
prognosis [43]. Therefore, understanding the biology of BC and exploring the metabolic 
pathways could help to identify potential novel therapeutic targets. 
Cancer cells must alter their metabolism in order to satisfy the demands of necessary energy 
and cellular building blocks. It is widely known that amino acid transport systems play a 
principle role in sustaining the proliferation of cancer cells via supplying the required amino 
acids for protein synthesis as well as activation of nutrient signalling through the mTORC1 
complex. This study has revealed, for the first time, that SLC7A5 is a key amino acid 
transporter in the more aggressive and highly proliferative ER+ tumours. 
 
SLC7A5 is located in 16q24.2. This study showed that SLC7A5 deletion, but not amplification, 
was significantly correlated with all the annotated genes located in the same chromosomal 
region, indicating that the deletion was not locus-specific. Interestingly, E-cadherin (CDH1), 
which located in 16q22.1, was also implicated. It is widely known that most lobular tumours 
harbour loss of heterozygosity (LOH) at chromosome 16 and miss the wild type CDH1 allele 
[45]. In this study, approximately 40% of METABRIC cases, with SLC7A5 loss, were 
associated with the invasive lobular histology. In addition, SLC7A5 protein expression in 
lobular carcinoma has a relatively lower mean rank value compared to the other histological 
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subtypes, confirming that deletions involve large segments of q16 which can reflect the BC 
phenotype. 
SLC7A5 is widely expressed in many human cancers and various cancer cell lines [46]. The 
current study included two large discovery and validation cohorts to confirm the significant 
association between the high SLC7A5 protein expression and the poor prognostic clinico-
pathological parameters, including larger tumour size, higher grade and poor NPI. Furthermore, 
high SLC7A5 expression was significantly associated with the higher expression of the 
proliferative marker (Ki67). This supports the results of previous studies which demonstrated 
that these two biomarkers are significantly correlated in tongue cancer [47], neuroendocrine 
carcinoma of the lung [48], thymic carcinomas [49] and breast cancer [50], indicating that 
SLC7A5 is critical for proliferation in cancer cells.  
With respect to the breast cancer ER+ subtypes, SLC7A5 expression was lower in ER+ tumours 
that have low proliferation (luminal A subtype) compared with the highly proliferative ER+ 
(luminal B) malignancies, and it was primarily associated with poor patient outcome and 
shorter DMFS in the latter class only. This is most likely due to their heavier energy and 
nutrient requirements for cell survival, proliferation, and metastasis. This is anticipated, as it 
has been shown that over-expression of SLC7A5 is actively involved in the proliferation of 
vascular smooth muscle cells [51] and it is co-expressed with vascular endothelial growth 
factor (VEGF) in primary and metastatic sites of many cancers [37] which may be implicated 
for the metastatic process.  In this study, luminal B subtype, showed the most significant 
positive correlation between the mRNA expression of SLC7A5 and VEGFA. In this regard, 
Bartlett et al included SLC7A5 as a part of the five gene Mammostrat® immunohistochemistry 
panel, where the higher expression is used to predict RFS, DRFS and OS in ER+ breast cancer 
during endocrine therapy [52]. However, they did not consider the different molecular subtypes 
of BC. 
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SLC7A5 mRNA and protein was also highly expressed in TNBC and HER2+, in concordance 
with Furuya et al [50]. However, in these subtypes the significant association between SLC7A5 
protein expression and patient outcome was only observed in the HER2+ tumours. Among all 
BC subtypes, SLC7A5 protein expression was an independent predictor for short BCSS in ER+ 
high proliferation tumours only.  In this regard, the larger sample size of ER+ high proliferation 
cases might reflect the stronger significance compared with the smaller sample size of HER2+ 
and TNBC tumours. We therefore suggest that further confirmation in larger cohorts of HER2+ 
and TN tumours is warranted. 
Previous studies have showed regulation of SLC7A5 by other proteins including the tumour 
oncogene Myc which induces SLC7A5 [4, 5]. In the current study, the relationship between 
SLC7A5 and other regulatory proteins in both mRNA and protein expression was investigated. 
A positive relationship was observed between SLC7A5 and Myc in both protein and mRNA 
levels, and this correlation remained significant only in luminal B subtype, when different 
subtypes were investigated. ATF4-dependent transcripts also encodes for SLC7A5 upon amino 
acid deprivation [39] and this study observed a positive correlation between ATF4 and 
SLC7A5 gene expression in line with expectations. A previous study showed that activation of 
the HIF2α pathway increases mTORC1 activity by upregulating expression of the amino acid 
carrier SLC7A5 [38] and the current study confirmed the positive correlation between HIF2α 
and SLC7A5, which was only observed in luminal B tumours. SLC7A5 functions by importing 
essential amino acids to cancer cells and research has detailed the role of amino acids, 
particularly leucine, in activating mTORC1, which in turn controls protein translation, cell 
proliferation and prevent apoptosis in malignant cells [2, 3]. This study showed a positive 
correlation between SLC7A5 and mTOR at the mRNA level. However, the protein levels of 
SLC7A5 showed conflicting results, where high SLC7A5 expression was associated with the 
lower expression of the mTORC1 phosphorylated at ser (2448), which was included in this 
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study. This was unsurprising as Cheng et al confirmed that phosphorylation of mTORC1 at ser 
(2448), which is stimulated by growth factors, was mutually exclusive with mTORC1 
phosphorylated at thr (2446), which is regulated by amino acids [53]. These observations may 
explain why SLC7A5 over-expression is primarily associated with poor outcome only in the 
high proliferative ER+ tumours. 
This study further investigated the association of SLC7A5 expression with other glutamine 
transporters, in which some variability in the expression of amino acid transporters across 
molecular subtypes was observed. For example, TN subtype was the main class which showed 
association with the transporters required for glutamine influx. Perhaps because it depends on 
delivery of glutamine instead of synthesis. In contrast, a positive correlation between SLC7A5 
and glutamine synthase enzyme GLUL was observed in Luminal A tumours, suggesting that 
this subtype might rely on glutamine neosynthesis rather than uptake. SLC1A5 functionally 
couples with SLC7A5 to allow the cellular influx and efflux of glutamine, as SLC1A5 mediates 
uptake of glutamine, while SLC7A5 uses intracellular glutamine concentrations to adjust 
essential amino acid cytoplasmic pool for metabolic demands and signalling to mTORC1 [15]. 
Here we observed that SLC7A5 and SLC1A5 are positively correlated in all the BC subtypes.  
Previous studies have raised awareness and revealed the importance of the Proline-Glutamine 
(Pro-Gln) regulatory axis in BC. SLC7A5 appears to have a pivotal role in this regulatory axis, 
as its expression was highly associated with the enzymes which mediate glutamate degradation 
to form the amino acid proline, which has been shown to play a role in assisting tumour growth 
by different mechanisms [54].  
Blocking SLC7A5 using its inhibitor, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid 
(BCH), efficiently decreased colony formation of MDA-MB-231 TNBC cells [55]. Even 
though the consequences of blocking SLC7A5 in the highly proliferative ER+ tumours remain 
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undetermined, this study suggests that SLC7A5 can potentially be used as a therapeutic target 
for luminal B BC. 
 
Conclusion 
This study revealed and confirmed that the glutamine transporter SLC7A5 was associated with 
poor prognostic characteristics and poor survival outcome. Over-expression of SLC7A5 appear 
to play a role in the proliferation and progression of the aggressive ER+ subtype of breast 
cancer, thus it could act as a potential therapeutic target. Functional assessment is necessary to 
reveal the specific role played by this amino acid transporter in the highly proliferative subclass 
and HER2+ BC. 
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Table 1. Clinicopathological associations of SLC7A5 protein expression in the discovery and 
validation breast cancer series. 
                                                     SLC7A5 protein 
                                                      Discovery set Validation set 
 
n (%) 
Mean   
 p-value 
Adjusted p-
value n (%) 
Mean  
 p-value 
Adjusted p-
value 
Patient’s Age  
≥50 395 (36) 582.20 
 
0.003 0.018 469 
(30) 
859.46 
 
7.0x10-12 <0.0001 
<50 714 (64) 539.95 
 
1070 
(70) 
730.79 
 
Tumour size  
≥ 2.0cm 532 (48) 521.22 
 
0.000002 <0.0001 939 
(61) 
729.47 
 
6.5x10-9 <0.0001 
˂ 2.0cm 577 (52) 586.14 
 
599 
(39) 
832.24 
 
Lympho-vascular Invasion  
Negative 722 (65) 545.17 
 
0.138 0.55 1086 
(71) 
743.95 
 
0.000007 <0.0001 
Positive 382 (35) 566.35 
 
451 
(29) 
829.31 
 
Site of distant metastasis 
Brain 
No 1044 
(94) 
546.62 
 
0.0001 0.0008 N/A 
Yes 61 (6) 662.27 
 
Lung 
No 1003 
(91) 
547.12 
 
0.007 0.04 N/A 
Yes 102 (9) 610.80 
 
Bone 
No 876 (79) 554.57 
 
0.651 1.30 N/A 
Yes 229 (21) 547.00 
 
Liver 
No 949 (86) 551.43 
 
0.568 1.70 N/A 
Yes 156 (14) 562.57 
 
 n (%) Mean   
 
rank 
 
 
 
 Rank 
χ2 p-value Adjusted p-
value 
n (%) Mean 
RankRank 
χ2 p-value Adjusted p-
value 
Tumour Grade 
1 190 (17) 450.77  
171.5 
 
5.6x10-38 
 
<0.0001 
231 
(15) 
585.30  
723.48 
 
7.7x10-72 
 
<0.0001 
2 366 (33) 473.19 622 
(40) 
647.46 
3 550 (50) 642.43 685 
(45) 
942.43 
Lymph Node Stage 
1 674 (61) 542.19  
4.811 
 
0.09 
 
0.45 
955 
(62) 
754.30  
12.56 
 
0.002 
 
0.004 
2 341 (31) 574.98 428 
(28) 
767.94 
3 91 (8) 556.75 153 
(10) 
858.69 
Nottingham Prognostic Index 
23 
 
Good 332 (30) 458.21  
102.4 
 
5.6x10-23 
 
<0.0001 
521 
(34) 
620.66  
156.60 
 
9.8x10-35 
 
<0.0001 
Moderate 593 (53) 578.27 768 
(50) 
828.08 
Poor 184 (17) 654.64 246 
(16) 
892.49 
IHC Subtypes 
ER+/HER2- Low 
Proliferation  
250 (27) 391.92  
 
178.4 
 
 
1.8x10-38 
 
 
<0.0001 
 
 
N/A ER+/HER2- High 
Proliferation 
351(38) 419.54 
Triple Negative 191 (20) 617.95 
HER2+ 143 (15) 519.69 
Histological type 
Ductal (including 
mixed) 
922 (83) 563.83  
 
69.05 
 
 
3.5x10-14 
 
 
<0.0001 
1335 
(87) 
782.19  
 
77.07 
 
 
7.2x10-16 
 
 
<0.0001 Lobular 101 (9) 454.17 120 (8) 584.17 
Medullary 26 (2) 832.02 13 
(0.8) 
1257.27 
Miscellaneous 7 (0.6) 440.50 9 (0.6) 1037.78 
Special type 53 (5.4) 472.75 57 
(3.6) 
655.12 
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Table 2. Copy number aberrations of SLC7A5 in METABRIC breast cancer series and their 
associations with clinicopathological parameters, MYC copy number aberrations and breast 
cancer subtypes. 
SLC7A5 copy number 
Gain                                          Loss 
 No 
n(%) 
Yes 
n(%) 
χ2  
(p-value) 
Adjusted 
p-value 
No 
n(%) 
Yes 
n(%) 
χ2  
(p-value) 
Adjusted 
p-value 
Age 
≥50 1520 (97.7) 36 (2.3) 0.405  
(0.524) 
1.572 1098 (70.6) 458 (29.4) 27.479 
(1.5x10-7) 
<0.0001 
˂50 372 (97.1) 11 (2.9) 321 (83.8) 62 (16.2) 
Tumour size  
≥ 2.0cm 1291 (97.0) 40 (3.0) 5.226 
(0.022) 
0.132 976 (73.3) 355 (26.7) 0.094 
(0.759) 
0.282 
˂ 2.0cm 614 (98.7) 8 (1.3) 452 (72.7) 170 (27.3) 
Tumour Grade 
1 170 (100.0) 0 (0.0) 10.154 
(0.006) 
 
0.042 
99 (58.2) 71 (41.8) 107.36 
4.8x10-24 
 
<0.0001 
2 756 (98.2) 14 (1.8) 495 (64.3) 275 (35.7) 
3 918 (96.4) 34 (3.6) 799 (83.9) 153 (16.1) 
Lymph Node Stage 
1 1012 (97.8) 23 (2.2) 0.474 
(0.789) 
 
1.578 
726 (70.1) 309 (29.9) 10.425 
(0.005) 
 
0.02 
2 606 (97.4) 16 (2.6) 480 (77.2) 142 (22.8) 
3 307 (97.2) 9 (2.8) 237 (75.0) 79 (25.0) 
Nottingham Prognostic Index 
Good 668 (98.2) 12 (1.8) 2.602 
(0.272) 
 
0.080 
418 (61.5) 262 (38.5) 76.132 
(2.9x10-17) 
 
<0.0001 
Moderate 1071 (97.3) 30 (2.7) 864 (78.5) 237 (21.5) 
Poor 192 (96.5) 7 (3.5) 168 (84.4) 31 (15.6) 
Histological type 
Ductal  1500 (97.2) 44 (2.8)  
 
6.880 
(0.230) 
 
 
 
1.150 
1154 (74.7) 390 (25.3)  
 
 29.544 
(0.00001) 
 
 
0.0001 
Lobular 145 (98.6) 2 (1.4) 88 (59.9) 59 (40.1) 
Medullary 30 (93.8) 2 (6.3) 30 (93.8) 2 (6.2) 
Miscellaneous 12 (100.0) 0 (0.0) 9 (75.0) 3 (25.0) 
Special type 113 (100.0) 0 (0.0) 74 (66.8) 39 (33.2) 
PAM50 subtype 
Luminal A 710 (98.9) 8 (1.1)  
 
40.515 
(3.3x10-8) 
 
 
<0.0001 
423 (58.9) 295 (41.1)  
 
248.3 
(1.4x10-52) 
 
 
<0.0001 
Luminal B 477 (97.7) 11 (2.3) 312 (63.9) 176(36.1) 
Basal 305 (92.7) 24 (7.3) 319 (97.0) 10 (3.0) 
HER2+ 235 (97.9) 5 (2.1) 219 (91.3) 21 (8.7) 
Normal-like 198 (99.5) 1 (0.5) 172 (11.9) 27(5.1) 
MYC Gain 
No 1228 (98.9) 14 (1.1) 25.0 
(5.5x10-7) 
<0.0001 1446 (73.3) 528 (26.7) 0.132 
(0.716) 
1.432 
Yes 703 (95.3) 35 (4.7) 4 (66.7) 2 (33.3) 
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Table 3A. Association of SLC7A5 protein expression and the expression of other molecular 
biomarkers in the discovery and validation sets. 
SLC7A5 protein 
 Discovery set Validation set 
 
n (%) 
       Mean  
 
p-value 
Adjusted  
p-value 
n (%) Mean  p-value 
Adjusted  
p-value 
ER 
Negative 270 (25) 722.20 
 
3.2x10-48 <0.0001 300 (19) 1094.70 4.6x10-76 <0.0001 
Positive 827 (75) 492.45 
 
1240 (81) 692.06 
PR 
Negative 435 (41) 619.12 
 
8.8x10-27 <0.0001 612 (42) 855.53 1.3x10-34 <0.0001 
Positive 630 (59) 473.54 
 
853 (58) 645.09 
HER2 
Negative 921 (87) 521.78 
 
0.00004 0.0001 1337 (92) 718.53 0.001 0.002 
Positive 143 (13) 601.54 
 
116 (8) 824.67 
Triple Negative 
No 896 (83) 503.50 
 
4.5x10-35 <0.0001 1286 (83) 696.76 1.5x10-62 <0.0001 
Yes 185 (17) 722.61 
 
225 (17) 1094.6 
Basal Phenotype 
No 794 (74) 510.96 
 
6.8x10-13 <0.0001 N/A 
Yes 285 (26) 620.90 
 
P53 protein 
Negative 760 (72) 499.14 
 
4.1x10-13 <0.0001 N/A 
Positive 298 (28) 606.92 
 
 
 
26 
 
Table 3B. Association of SLC7A5 mRNA expression and the expression of other molecular 
biomarkers in the METABRIC series. 
SLC7A5 mRNA expression 
 
n (%) Mean  t-test p-value 
Adjusted 
p-value 
Estrogen Receptor 
Negative 474 (24) 9.543 26.90 5.6x10-113 <0.0001 
Positive 1506 (76) 7.943 
Progesterone Receptor 
Negative 940 (47) 8.862 18.73 1.07x10-71 <0.0001 
Positive 1040 (53) 7.841 
HER2 
Negative 1733 (88) 8.216 -12.35 1.1x10-29 <0.0001 
Positive 247 (12) 9.095 
Triple Negative (ER-, PR-, HER2-) 
No 1660 (84) 8.065 -22.12 1.9x10-73 <0.0001 
Yes 320 (16) 9.676 
Basal Phenotype 
No 1645 (83) 8.036 -25.70 1.5x10-91 <0.0001 
Yes 329 (17) 9.788 
TP53 mutation 
Wild-type 721 (88) 8.132 -7.47 1.2x10-11 <0.0001 
Mutation 99 (12) 9.148 
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Table 4. Correlation of SLC7A5 expression with the expression of other related genes in the 
METABRIC data. 
 SLC7A5 mRNA expression 
       All cases 
     (n=1,980) 
    Luminal A 
  (n=368) 
Luminal B 
 (n=367) 
HER2+ 
(n=110) 
Triple negative 
(n=150) 
                                                          Correlation Coefficient  
                                                         (p-value) 
Adjusted p-value 
Regulatory and other associated genes 
MYC 0.133  
(2.4x10-9) 
<0.0001 0.012 
(0.752) 
4.145 0.155 (0.001) 0.019 0.066 
(0.310) 
4.650 0.103 
(0.062) 
0.434 
mTOR 0.085  
(0.0001) 
0.001 -0.005 
(0.904) 
1.824 0.088 (0.052) 0.728 -0.023 
(0.723) 
5.784 0.067 
(0.226) 
1.130 
VEGFA 0.352  
(6.4x10-59) 
<0.0001 0.166 
(0.000008) 
0.0002 0.260 
(5.3x10-9) 
<0.0001 0.269 
(0.00002) 
0.0005 0.244 
(0.000008) 
0.0002 
HIF2A -0.050  
(0.028) 
0.168 -0.023 
(0.536) 
4.896 0.215 
(0.000002) 
<0.0001 0.112 
(0.083) 
1.328 -0.282 
(1.8x10-7) 
<0.0001 
ATF4 0.159  
(1.0x10-12) 
<0.0001 -0.029 
(0.433) 
5.100 0.057  
(0.208) 
2.080 0.143 
(0.026) 
0.468 0.108 
(0.050) 
0.450 
Glutamine-proline regulatory axis 
GLS 0.048  
(0.032) 
0.192 0.008 
(0.829) 
3.428 0.055  
(0.222) 
1.998 -0.006 
(0.927) 
4.635 -0.115 
(0.038) 
0.456 
ALDH4A1 -0.053  
(0.019) 
0.133 0.018 
(0.638) 
4.512 0.063  
(0.163) 
1.793 -0.028 
(0.663) 
5.967 -0.134 
(0.015) 
0.225 
PRODH 0.004  
(0.858) 
1.716 -0.034 
(0.369) 
4.763 -0.032 
(0.483) 
2.415 0.037 
(0.573) 
5.73 0.030 
(0.582) 
1.746 
PYCR1 0.32 
(1.5x10-50) 
<0.0001 0.143 
(0.0001) 
0.001 0.253 
(1.3x10-8) 
<0.0001 0.210 
(0.001) 
0.024 0.303 
(1.9x10-8) 
<0.0001 
ALDH18A1 0.222 
(1.6x10-23) 
<0.0001 0.151 
(0.00004) 
0.0008 0.144  
(0.001) 
0.018 0.168 
(0.009) 
0.180 0.356 
(2.9x10-11) 
<0.0001 
GLUL -0.18  
(3.3x10-16) 
<0.0001 0.134 
(0.0003) 
0.005 0.008  
(0.863) 
1.726 -0.001 
(0.991) 
1.982 -0.122 
(0.028) 
0.392 
GLUD1 -0.38  
(4.3x10-69) 
<0.0001 -0.161 
(0.00001) 
0.0002 -0.237 
(1.1x10-7) 
<0.0001 -0.148 
(0.022) 
0.418 -0.112 
(0.042) 
0.420 
Glutamine/Glutamate transporters 
SLC1A5 0.29  
(4.5x10-41) 
<0.0001 0.170 
(0.000005) 
0.0001 0.150  
(0.001) 
0.017 0.208 
(0.001) 
0.023 0.25 
(0.000002) 
<0.0001 
SLC3A2 0.17  
(1.1x10-14) 
<0.0001 0.067 
(0.072) 
3.780 0.193 
(0.00001) 
0.0002 0.184 
(0.004) 
0.084 0.158 
(0.004) 
0.064 
SLC6A19 0.004  
(0.869) 
1.738 0.041 
(0.273) 
4.428 -0.008 
(0.859) 
2.577 0.047 
(0.473) 
5.676 -0.103 
(0.061) 
0.488 
SLC7A6 0.362 
(2.7x10-62) 
<0.0001 0.254 
(5.3x10-12) 
<0.0001 0.33  
(2.0x10-14) 
<0.0001 0.284 
(0.000008) 
0.0002 0.071 
(0.201) 
1.206 
SLC7A7 0.19  
(4.6x10-19) 
<0.0001 0.007 
(0.857) 
2.712 0.085  
(0.061) 
0.793 0.041 
(0.530) 
5.830 -0.22 
(0.00005) 
0.0001 
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SLC7A8 -0.42 
(1.1 x10-88) 
<0.0001 -0.115 
(0.002) 
0.034 -0.103 
(0.022) 
0.352 -0.203 
(0.002) 
0.044 -0.40 
(3.9x10-14) 
<0.0001 
SLC7A9 -0.068  
(0.002) 
0.01 0.025 
(0.510) 
4.82 0.044  
(0.333) 
2.331 -0.123 
(0.056) 
0.952 0.283 
(1.8x10-7) 
<0.0001 
SLC38A1 -0.10 
(0.000003) 
<0.0001 -0.041 
(0.270) 
3.549 0.039  
(0.391) 
2.346 0.053 
(0.413) 
5.369 0.113 
(0.041) 
0.451 
SLC38A2 -0.055  
(0.015) 
0.120 -0.074 
(0.048) 
1.05 -0.103 
(0.022) 
0.330 0.007 
(0.917) 
5.502 -0.119 
(0.032) 
0.416 
SLC38A3 0.18  
(8.3x10-17) 
<0.0001 0.140 
(0.0001) 
0.002 0.046  
(0.311) 
2.488 0.003 
(0.958) 
2.874 0.196 
(0.0003) 
0.005 
SLC38A5 0.011  
(0.627) 
2.574 -0.069 
(0.066) 
1.08 -0.077 
(0.090) 
1.080 -0.017 
(0.793) 
5.551 -0.017 
(0.757) 
1.514 
SLC38A7 0.306 
(3.8x10-44) 
<0.0001 0.270 
(2.0x10-13) 
<0.0001 0.32  
(1.2x10-13) 
<0.0001 0.064 
(0.324) 
4.536 0.177 
(0.001) 
0.017 
SLC38A8 0.023  
( 0.312) 
1.560 -0.019 
(0.612) 
4.466 0.011  
(0.801) 
3.204 -0.006 
(0.930) 
3.720 -0.039 
(0.482) 
1.928 
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Table 5. Correlation between SLC7A5 protein expression and other biomarkers in the 
discovery set. 
SLC7A5 protein 
Biomarker Correlation coefficient P-value Adjusted p-
value 
c-MYC 0.164 8.2x10-7 <0.0001 
Ki67 0.311 1.1x10-21 <0.0001 
P-mTORC1 -0.150 0.00001 <0.0001 
PIK3CA 0.190 3.4x10-7 <0.0001 
SLC1A5 0.331 1.1x10-25 <0.0001 
GLUD1 0.053 0.09 0.180 
GLS 0.371 2.2x10-30 <0.0001 
PYCR1 0.283 1.07x10-16 <0.0001 
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Table 6. SLC7A5 protein expression and patient outcome in the combined, discovery and 
validation, sets in all cases and in ER-positive high proliferation tumours. 
SLC7A5 protein 
All cases                ER+ high proliferation  
Parameter Hazard ratio  
(95% CI) 
p-value 
Adjusted 
p-value 
Hazard ratio  
(95% CI) 
p-value 
Adjusted 
p-value 
SLC7A5 1.001 (1.000-1.003) 0.063 0.126 1.004 (1.001-1.006) 0.006 0.024 
Lymph 
nodestage 
2.060 (1.813-2.341) 1.7x10-28 <0.0001 1.756 (1.427-2.161) 1.04x10-7 <0.0001 
Size 1.365 (1.111-1.678) 0.003 0.009 1.169 (0.838-1.632) 0.358 0.716 
Grade 
2.454 (2.023-2.977) 1.8x10-20 <0.0001 1.756 (1.154-2.672) 0.009 0.027 
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Supplementary Table 1. Clinicopathological parameters of the METABRIC and Nottingham 
discovery and validation series. 
 METABRIC series  
n (%) 
Nottingham 
discovery set 
n (%) 
Nottingham 
Validation set 
n (%) 
Age    
≥ 50 years 1426 (78.6) 714 (61.3) 1070 (69.5) 
˂ 50 years 424 (21.4) 395 (38.7) 469 (30.5) 
Tumour size    
≥ 2cm 1337 (68.2) 577 (52.0) 599 (38.9) 
˂2cm 623 (31.8)       532 (48.0) 939 (61.1) 
Grade    
1 169 (9.0) 190 (17.2) 231 (15.0) 
2 770 (40.7) 366 (33.1) 622 (40.4) 
3 952 (50.3) 550 (49.7) 685 (44.5) 
Tumour type    
Ductal (including mixed) 1545 (83.6) 922 (83.1) 1335 (86.9) 
Lobular 148 (8.0) 101 (9.1) 120 (7.8) 
Medullary-like 32 (1.7) 26 (2.3) 13 (0.8) 
Miscellaneous 12 (0.6)         7   (0.6)  9  (0.6) 
Special type 113 (6.1) 53 (4.9) 60 (3.9) 
Vascular Invasion    
Definite Not available 382 (34.6) 451 (29.3) 
Negative/Probable 
 
722 (65.4) 1086 (70.7) 
Lymph Node Stage  
1 1035 (52.5) 674 (70.0) 955 (62.2) 
2 623 (31.5) 341 (30.8) 428 (27.9) 
3 315 (16.0) 91   (8.2) 153 (10.0) 
Follow-up Status    
Alive     1070 (55.7) 569 (51.3) 1110 (72.2) 
Died from Breast Cancer 505 (26.3) 365 (33.0) 282 (18.3) 
Died from other causes 345 (18.0) 175 (15.7) 146 (9.5) 
Estrogen Receptor    
Negative 472 (23.8)   270 (24.6) 300 (19.5) 
Positive 1508 (76.2) 827 (75.4) 1240 (80.5) 
Progesterone Receptor    
Negative 938 (47.4) 435 (40.8) 612 (41.8) 
Positive 1042 (52.6) 630 (59.2) 853 (58.2) 
HER2 status    
Negative 1734 (87.5) 921 (86.6) 1376 (89.9) 
Positive 246 (12.5) 143(13.4) 155 (10.1) 
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Supplementary table 2. List of genes whose copy number loss was significant 
associatedwith SLC7A5 deletion in the METABRIC and TCGA data. 
 
  
Gene 
symbol 
Description Chromosomal 
location 
TCGA 
P-value 
METABRIC 
P-value 
SIAH1 siah E3 ubiquitin protein ligase 1 16q12.1 1.5x10-3 1.3x10-3 
ABCC11 ATP binding cassette subfamily C 
member 11 
16q12.1 1.5x10-3 1.3x10-3 
CYLD CYLD lysine 63 deubiquitinase 16q12.1 1.5x10-3 1.3x10-3 
MMP2 matrix metallopeptidase 2 16q12.2 1.2x10-4 1.8x10-4 
RBL2 RB transcriptional corepressor like 2 16q12.2 6.1x10-3 4.3x10-4 
AMFR autocrine motility factor receptor 16q13 3.1x10-5 1.8x10-4 
MMP15 matrix metallopeptidase 15 16q21 1.2x10-4 1.8x10-4 
USB1 U6 snRNA biogenesis phosphodiesterase 
1 
16q21 1.2x10-4 1.8x10-4 
CX3CL1 C-X3-C motif chemokine ligand 1 16q21 1.2x10-4 1.8x10-4 
NOL3 nucleolar protein 3 16q22.1 8.8x10-7 3.3x10-3 
NQO1 NAD(P)H quinone dehydrogenase 1 16q22.1 2.3x10-8 2.2x10-4 
TERF2 telomeric repeat binding factor 2 16q22.1 8.8x10-7 8.02x10-3 
CBFB core-binding factor beta subunit 16q22.1 8.8x10-7 6.1x10-3 
CDH1 cadherin 1 16q22.1 1.2x10-5 3.4x10-4 
CDH3 cadherin 3 16q22.1 4.3x10-6 1.4x10-4 
CTCF CCCTC-binding factor 16q22.1 8.8x10-7 1.3x10-5 
E2F4 E2F transcription factor 4 16q22.1 8.8x10-7 9.4x10-6 
PHLPP2 PH domain and leucine rich repeat 
protein phosphatase 2 
16q22.2 1.3x10-7 2.2x10-6 
ZFHX3 zinc finger homeobox 3 16q22.2-16q22.3 1.3x10-7 1.1x10-6 
BCAR1 BCAR1, Cas family scaffolding protein 16q23.1 3.8x10-9 1.8x10-5 
WWOX WW domain containing oxidoreductase 16q23.1-16q23.2 3.7x10-8 6.3x10-6 
ATMIN ATM interactor 16q23.2 1.2x10-11 3.1x10-5 
MAF MAF bZIP transcription factor 16q23.2 9.5x10-11 4.5x10-7 
OSGIN1 oxidative stress induced growth inhibitor 
1 
16q23.3 3.8x10-11 1.1x10-7 
CDH13 cadherin 13 16q23.3 2.1x10-12 1.1x10-6 
FOXF1 FOXF1 adjacent non-coding 
developmental regulatory RNA 
16q24.1 2.4x10-13 1.1x10-7 
WFDC1 WAP four-disulfide core domain 1 16q24.1 2.1x10-12 1.1x10-6 
FBXO31 F-box protein 31 16q24.2 2.4x10-13 1.1x10-7 
FANCA Fanconi anemia complementation group 
A 
16q24.3 2.1x10-12 5.4x10-4 
CBFA2T3 CBFA2/RUNX1 translocation partner 3 16q24.3 2.1x10-12 7.8x10-5 
CDT1 chromatin licensing and DNA replication 
factor 1 
16q24.3 2.1x10-12 7.8x10-5 
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Supplementary table 3. SLC7A5 mRNA and patient outcome. 
 
 
 
 
  
SLC7A5 mRNA 
Parameter Hazard ratio  
(95% CI) 
p-value 
Adjusted p-
value 
SLC7A5 1.121 (1.039-1.209) 0.003 0.006 
LN stage 1.877 (1.656-2.129) 8.9x10-23 <0.0001 
Size 1.550 (1.219-1.971) 0.0003 0.001 
Grade 1.331 (1.108-1.599) 0.002 0.006 
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Figure legends  
Figure 1: SLC7A5 protein expression in invasive breast cancer cores. A) Negative IHC 
expression, B) positive IHC expression. 
Figure 2: SLC7A5 copy number aberrations and relationship with mRNA expression in the 
METABRIC cohort using One-way ANOVA with post-hoc tukey test. 
 
Figure 3: SLC7A5 mRNA expression and its association with clinicopathological parameters 
and molecular subtypes: A) SLC7A5 and tumour size, B) SLC7A5 and tumour grade, C) 
SLC7A5 and lymph node stage, D) SLC7A5 and NPI, E) SLC7A5 and METABRIC Integrative 
Clusters, F) SLC7A5 and PAM50 subtypes, G) SLC7A5 and SMCGENE subtypes in the 
METABRIC cohort using One-way ANOVA with post-hoc tukey test. 
 
Figure 4. SLC7A5 mRNA and breast cancer patient outcome. A) SLC7A5 vs BCSS in all 
cases, B) SLC7A5 vs BCSS in Luminal A tumours, C) SLC7A5 vs BCSS in Luminal B 
tumours, D) SLC7A5 vs BCSS in Triple Negative tumours, E) SLC7A5 vs BCSS in HER2+ 
tumours. 
Figure 5. SLC7A5 and breast cancer patient outcome. A) SLC7A5 vs BCSS in all discovery 
set cases , B) SLC7A5 vs BCSS in all validation set cases, C) SLC7A5 vs BCSS of ER+- Low 
Proliferation tumours in the combined discovery and validation cases, D) SLC7A5 vs BCSS 
of ER+- High Proliferation tumours in the combined discovery and validation cases, E) 
SLC7A5 vs BCSS of Triple Negative tumours in the combined discovery and validation cases, 
F) SLC7A5 vs BCSS HER2+ tumours in the combined discovery and validation cases. 
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Supplementary Figure 1: SLC7A5 gene expression and its association, using Breast Cancer 
Gene-Expression Miner v4.0, with: A) tumour grade, B) NPI, C) ER status, D) PR status, E) 
HER2 status, F) Triple Negative status, G) PAM50 subtypes.  
Supplementary Figure 2. SLC7A5 vs DMFS in A) all cases in the discovery set, B) All cases 
in the validation set, C) ER+- Low Proliferation tumours in the combined discovery and 
validation set cases, D) ER+- High Proliferation tumours in the combined discovery and 
validation set cases, E) Triple negative tumours in the combined discovery and validation set 
cases, F) HER2+ tumours in the combined discovery and validation set cases.  
Supplementary Figure 3: SLC7A5 mRNA and breast cancer patient outcome using Breast 
Cancer Gene-Expression Miner: K) Unselected cases, L) ER+ disease, M) ER- disease.  
Supplementary Figure 4. SLC7A5 mRNA expression, in the TCGA data, and its association 
with A) Copy Number Alteration, B) staging system, C) ER status, D) PR status, E) HER2 
status. 
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